Table 4 Taste-related adverse events (conventional analysis)
Filapixant (N = 23) | Placebo (N = 23) | |||||||
|---|---|---|---|---|---|---|---|---|
Adverse event | 20 mg | 80 mg | 150 mg | 250 mg | (20 mg) | (80 mg) | (150 mg) | (250 mg) |
(MedDRA preferred term) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
Ageusia | 0 | 1 (4.3%) | 1 (4.3%) | 0 | 0 | 0 | 0 | 0 |
Dysgeusia | 1 (4.3%) | 0 | 3 (13.0%) | 5 (21.7%) | 0 | 0 | 2 (8.7%) | 0 |
Hypogeusia | 0 | 1 (4.3%) | 1 (4.3%) | 1 (4.3%) | 0 | 0 | 0 | 0 |
Taste disorder NOS | 0 | 1 (4.3%) | 4 (17.4%) | 1 (4.3%) | 1 (4.3%) | 0 | 0 | 0 |
Total number of patients reporting such events | 1 (4.3%) | 2 (8.7%) | 8 (34.8%) | 6 (26.1%) | 1 (4.3%) | 0 | 2 (8.7%) | 0 |